Citations 2
Early Adoption of Suzetrigine After FDA Approval: Inpatient and Outpatient Practice Patterns
Colontonio, Matthew M. , Kivanc, Tugba Yavuz, Gruenbaum, Benjamin F., Martinez, Fiorela , Ancayan, Sareidenn , Gruenbaum, Benjamin F. , Logvinov, Ilana I. , Gruenbaum, Benjamin Fredrick , Kivanc, Tugba Yavuz, Hunt, Christine
Anesthesia & Analgesia | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Use of Suzetrigine, a Selective Sodium Channel Blocker, in Postoperative Pain Management for an Adolescent Patient With Hereditary Neuropathy: A Case Report
Nimma, Sindhuja, Kivanc, Tugba Yavuz, Colontonio, Matthew M. , Nimma, Sindhuja Reddy, Kivanc, Tugba Yavuz
A&A Practice | December 3, 2025 | Volume: 19 | Issue: 12 | Pages: e02114
Suzetrigine is a unique, nonopioid oral analgesic that selectively inhibits voltage-gated sodium channels in peripheral nerves. The Food and Drug Administration (FDA) recently approved it, and we present the first successful use of suzetrigine in a 16-year-old boy with hereditary neuropathy who underwent foot reconstruction surgery. His postoperative pain management plan included a sciatic nerve catheter, a 14-day course of suzetrigine, opioids, and home medications. His pain was well controlled with no side effects. Within 24 hours of stopping suzetrigine, the patient’s pain rapidly intensified, suggesting suzetrigine’s effectiveness in postoperative pain management in an adolescent patient with neuropathy.